This Book >>

  • 316pp. Published March 2016
  • Scientific Research Publishing, Inc.,USA
  • Category: Medicine & Healthcare
  • ISBN: 978-1-61896-167-9
  • (Hardcover) USD 89.00
  • ISBN: 978-1-61896-166-2
  • (Paperback) USD 69.00
Authors/Editors Price: 40% off
Buy at: bookorder@scirp.org

Connect with SCIRP >>

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)
Home > Books > Advances in Drug Resistance of HIV-1
Advances in Drug Resistance of HIV-1
  • Description
  • Author(s) Information

HIV can be divided into two major types, HIV type 1 (HIV-1) and HIV type 2 (HIV-2). HIV-1 is related to viruses found in chimpanzees and gorillas living in western Africa, while HIV-2 viruses are related to viruses found in the endangered West African primate sooty mangabey. HIV-1 viruses may be further divided into groups. The HIV-1 group M viruses predominate and are responsible for the AIDS pandemic. Group M can be further subdivided into subtypes based on genetic sequence data. Some of the subtypes are known to be more virulent or are resistant to different medications. Likewise, HIV-2 viruses are thought to be less virulent and transmissible than HIV-1 M group viruses, although HIV-2 is known to cause AIDS.

 

In the present book, thirteen typical literatures about drug resistance of HIV-1 published on international authoritative journals were selected to introduce the worldwide newest progress, which contains reviews or original researches on medical science, virology, epidemiology, ect. We hope this book can demonstrate advances in drug resistance of HIV-1 as well as give references to the researchers, students and other related people.

Components of the Book:
  • Chapter 1
    Diminished Transmission of Drug Resistant HIV-1 Variants with Reduced Replication Capacity in a Human Transmission Model
  • Chapter 2
    Rilpivirine Analogs Potently Inhibit DrugResistant HIV1 Mutants
  • Chapter 3
    Persistence of Frequently Transmitted Drug-resistant HIV-1 Variants Can Be Explained by High Viral Replication Capacity
  • Chapter 4
    Characterization of Two HIV-1 Infectors during Initial Antiretroviral Treatment, and the Emergence of Phenotypic Resistance in Reverse Transcriptase-Associated Mutation Patterns
  • Chapter 5
    Structural Studies on Molecular Mechanisms of Nelfinavir Resistance Caused by Non-Active Site Mutation V77I in HIV-1 Protease
  • Chapter 6
    A Common Mechanism of Clinical HIV-1 Resistance to the CCR5 Antagonist Maraviroc despite Divergent Resistance Levels and Lack of Common gp120 Resistance Mutations
  • Chapter 7
    Analysis of 454 Sequencing Error Rate, Error Sources, and Artifact Recombination for Detection of Low-Frequency Drug Resistance Mutations in HIV-1 DNA
  • Chapter 8
    Low Prevalence of the Transmitted HIV-1 Drug Resistance among Newly Diagnosed HIV-1 Individuals in Jiangsu Province, China during 2009–2011
  • Chapter 9
    HIV-1 Transmitted Drug Resistance Mutations among Antiretroviral Therapy-Naïve Individuals in Surabaya, Indonesia
  • Chapter 10
    Exploiting HIV-1 Protease and Reverse Transcriptase Cross-Resistance Information for Improved Drug Resistance Prediction by Means of Multi-Label Classification
  • Chapter 11
    HIV‑1 Protease Inhibitor Drug Resistance in Kenyan Antiretroviral Treatment‑Naive and -Experienced Injection Drug Users and Non-Drug Users
  • Chapter 12
    High Level of HIV-1 Drug Resistance among Patients with HIV-1 and HIV-1/2 Dual Infections in Guinea-Bissau
  • Chapter 13
    Sequence and Structure Based Models of HIV-1 Protease and Reverse Transcriptase Drug Resistance
Readership: Students, academics, teachers and other people attending or interested in Advances in Drug Resistance of HIV-1
comments powered by Disqus